STAT3 and neoplasm: Nonetheless, targeting the common and functionally well-defined STAT3 in genetically stable, tumor-associated myeloid cells provides for a broadly applicable immunotherapeutic strategy that could overcome the limitations of current cancer immunotherapies [10,15,16].